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SUMMARY
Broadly neutralizing antibodies (bNAb) that target a conserved region of a viral antigen hold 
significant therapeutic promise. CR8020 is a bNAb that targets the stem region of influenza A 
virus (IAV) hemagglutinin (HA). CR8020 is currently being evaluated for prophylactic use against 
group 2 IAVs in phase II studies. Structural and computational analyses reported here indicate that 
CR8020 targets HA residues that are prone to antigenic drift and host selection pressure. 
Critically, CR8020 escape mutation is seen in certain H7N9 viruses from recent outbreaks. 
Furthermore, the ability of the bNAb Fc region to effectively engage activating Fcγ receptors 
(FCγR) is essential for antibody efficacy. In this regard, our data indicate that the membrane could 
sterically hinder the formation of HA-CR8020-FcγRIIa/HA-IgG-FcγRIIIa ternary complexes. 
Altogether, our analyses suggest that epitope mutability and accessibility to immune complex 
assembly are important attributes to consider when evaluating bNAb candidates for clinical 
development.
INTRODUCTION
Recently, technologies related to the characterization and isolation of B-cells from infected 
or vaccinated individuals have identified broadly neutralizing antibodies (bNAbs) targeting 
highly diverse pathogens, such as HIV (Zwick et al., 2003), (Wu et al., 2010), (Scheid et al., 
2011), (Pejchal et al., 2010), (Pejchal et al., 2011), (Zwick et al., 2001) and influenza (Ekiert 
et al., 2011), (Sui et al., 2009), (Dreyfus et al., 2013), (Corti et al., 2011). Analysis of these 
antibodies, including the epitopes they target and their germline of origin, provides 
information useful to vaccine design (Kwong et al., 2011), (Nabel, 2012), (Steel et al., 
2010). In addition, in the absence of the development of a universal, broadly protective 
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vaccine strategy for viral diseases such as influenza, passive immunization using antibodies 
could help treat the disease and protect so-called “at risk” populations, such as the 
immunocompromised and elderly individuals. While early bNAbs for HIV, such as 2F5 
(Muster et al., 1993) and 4E10 (Zwick et al., 2001) exhibited polyreactivity and unusually 
short half-lives in phase I trials, passive immunization for influenza and HIV has progressed 
to the point that multiple antibodies are now entering human clinical trials.
In the case of influenza, efforts were made in the past to isolate cross-reactive bNAbs 
targeting the conserved, relatively sub-dominant epitopes of the virus (Graves et al., 
Virology 1983 and Okuno et al., JVI 1993). With advances in technologies, the recent years 
have seen a tremendous surge in the development of bNAbs against the hemagglutinin (HA) 
protein of influenza A virus (Ekiert et al., 2011), (Sui et al., 2009), (Dreyfus et al., 2013), 
(Corti et al., 2011). A bNAb targets a conserved region of the antigen and is thereby 
efficacious against a wide range of strains. The applicability of such bNAbs in a 
prophylactic setting is being evaluated for CR8020 (Ekiert et al., 2011), which targets group 
2 influenza A viruses. Currently, CR8020 is evaluated both as a single agent 
(NCT01938352) and in combination with a group 1 bANb – CR6261 – (NCT01992276) in 
two separate Phase II studies. In these studies, the prophylactic potential of CR8020 is being 
evaluated in individuals who are infected with a group 2 H3N2 virus. At present, CR8020 is 
the most advanced anti-group 2 bNAb undergoing clinical trials. The H3N2 subtype has 
been circulating in humans since 1968, causing more than 400,000 deaths in the United 
States alone (Kawaoka et al., 1989), (Jansen et al., 2007), (Iwane et al., 2004). Besides 
H3N2, another group 2 subtype, the avian-origin H7N9, recently led to 144 cases of 
infection in China (Gao et al., 2013). Of these cases, 46 died (>30% mortality), raising 
concerns that the virus might change into a form that is more transmissible in humans. 
Further troubling is the fact that the recent H7N9 strains are resistant to M2 channel blockers 
and some strains are also displaying resistance to Tamiflu and Relenza (Hai et al., 2013). In 
light of the above, an understanding of the biological activity of CR8020, as well as clinical 
considerations, particularly against group 2 subtypes H3N2 and H7N9, becomes extremely 
important.
RESULTS
CR8020 binding residues on HA are susceptible to sequence drift and potential for escape 
mutations
CR8020 targets an immune-subdominant, relatively conserved membrane-proximal stem 
region of HA, thus preventing fusion and viral entry through: (1) inhibiting fusogenic 
conformational change and/or (2) inhibiting cleavage of HA0 by host proteases. 
Interestingly, Ekiert DC et. al. identified two CR8020 escape mutations – D19N and G33E 
in HA2 domain – which also occur in select natural H3 strains (Ekiert et al., 2011). In their 
study, the antibody was found to be less sensitive to other epitope changes observed in 
naturally occurring H3N2 strains. To identify the potential for escape mutations that are not 
readily observed in nature, we applied our novel computational approach, based on atomic 
interaction networks, to examine the relationship between amino acids within the epitope 
and to evaluate the mutability of the individual sites. A detailed description of the atomic 
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interaction network approach, called SIN (Significant Interactions Network), can be found 
elsewhere (Soundararajan et al., 2011). A brief description of the network approach can be 
found in the METHODS section.
Previously, we applied this approach to successfully demonstrate how immunologic, 
pressure-induced antigenic changes on the globular head region of A/Puerto Rico/8/1934 
(PR8) H1N1 influenza A virus can affect host receptor-binding affinity through inter-residue 
interactions (Soundararajan et al., 2011). From sequence analyses, 9 out of 13 CR8020 
epitope sites have seen amino acid variation (METHODS). Furthermore, SIN scores suggest 
that only four sites – R25, Q34, N146 and G150 – are under mutational constraints (SIN > 
0.2), suggesting the potential for antiviral-associated escape mutations (METHODS and 
Table 1). Using the co-crystal structure of CR8020 Fab in complex with HA of A/Hong 
Kong/1/1968 (H3N2) (PDB: 3SDY), the mutable sites were analyzed, and HA mutations 
that contribute to destabilizing the epitope-paratope interface without affecting HA stability 
(METHODS) were predicted with atomic network interactions and verified with physics-
based modeling functions (Table 1). Interestingly, the predicted escape mutations are a 
single base pair change away from the wild type sequence, implying potential for emergence 
of mutants that can escape antibody detection and neutralization. Similarly, analysis to 
determine potential escape mutations for H7 HA using a model of CR8020 docked with A/
Shanghai/02/2013(H7N9) HA (PDB: 4LN3) yielded 16 mutations at 7 mutable sites (Table 
2).
Changes in CR8020 binding residues may be driven by host selection 
pressure—Critically, the D19N CR8020 escape mutation is seen in one of the circulating 
H7N9 outbreak viruses – A/Wuxi/1/2013 (H7N9) – suggesting that CR8020 is likely to be 
even less effective against this recent outbreak virus. Notably, this mutation has not been 
previously observed in an Asian H7 virus. Out of the 612 H7 HA sequences available in the 
public database, 514 sequences (~84%) contain D at position 19, and 98 sequences (~16%) 
contain N. The fact that HA can acquire stem mutations begs the question whether these 
mutations are associated with antigenic drift and immune escape. Until recently, the 
immunodominance of the head region and the potency of antibodies directed to the head 
yielded the concept of the canonical antigenic site model of HA, wherein a majority of the 
antigenic sites are concentrated near the receptor binding site region (Soundararajan et al., 
2011), (Gerhard et al., 1981), (Wiley et al., 1981), (Wilson et al., 1981), (Tsuchiya et al., 
2001). However, recent vaccine clinical studies however have identified fusion-inhibiting 
stem binding bNAbs in humans (Hardelid et al., 2010), (Wei et al., 2010), antibodies which 
are more broadly reactive. Additionally, analyses of B-cell epitopes from the Immune 
Epitope Database (http://www.iedb.org) highlight the involvement of many HA2 stem 
residues, including amino acids within the CR8020 epitope, as part of many B-cell epitopes 
(Figure S1), indicating the ability of the stem region to induce protective response. To 
determine whether the D19N substitution is associated with antigenic drift, we considered 
accompanying changes within close spatial and temporal proximity (METHODS), as such 
co-evolving multiple mutations are probably indicative of immune pressure exerted by host 
antibodies. Interestingly, residues at 326 of HA1 and 160 of HA2 co-evolve along with site 
19 of HA2 (Figure 1A–D). The spatial proximity of these sites (Figure 1E) and their co-
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evolution are consistent with the changes observed at globular head B-cell epitopes of HA 
(Shih AC Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6283–8, Huang JW BMC 
Bioinformatics. 2009 Jan 30;10 Suppl 1:S41), implying stem antigenic evolution as a result 
of host selection pressure. It must be noted that the chance occurrence of such co-evolving 
sites in the stem region where mutation rates are low is highly unlikely. In this context, 
given the differences within the epitope for H7 compared to H3, we anticipate that CR8020 
would bind with low affinity, a result which was verified experimentally. Whereas CR8020 
bind with relatively high affinity to HA of H3N2 strains such as A/Brisbane/10/2007 (IC50 
of 3.36 nM) and A/Wyoming/3/2003 (IC50 of 0.06 nM), CR8020 did not show binding to A/
Shanghai/02/2013, a representative H7N9 strain (Figure 1F).
Membrane may sterically hinder binding of Fcγ R to Fc within the immune complex
In addition to mutability of the epitope, on the basis of a recent study by DiLillo DJ et. al. 
(Dilillo et al., 2014), another factor that could limit the efficacy of bNAbs is the ability of 
the Fc region of the antibody to effectively engage Fcγ receptors in vivo. This study 
compared the neutralization potential of head binding strain-specific HA antibodies against 
stem binding bNAbs and found that, although recognition of a “functional” epitope by the 
Fab arm of an antibody is pivotal for in vitro neutralization of the virus, the Fc-Fcγ 
interaction and activation of antibody dependent cellular cytotoxicity (ADCC) was critical 
for the in vivo efficacy of stem binding bNAbs. The Fc-Fcγ receptor interaction is key for 
regulating a host of innate and adaptive immune responses in vivo. Antibodies can engage 
both activating and inhibitory Fcγ receptors as well as mediate killing of infected cells 
expressing HA by ADCC through interaction with activating Fcγ receptors (FcγRIIa and 
FcγRIIIa). Given that CR8020 targets a membrane-proximal epitope (distance between base 
of the epitope and membrane is approximately 14A°), we assessed whether accessing the 
Fc-tail of the CR8020-HA immune complex could be an issue for the activating FcγRs. We 
evaluated the ability of IgG CR8020 to engage Fcγ receptors by building a molecular model 
of the activation complex of FcγRIIa/RcγIIIa in the liganded state (HA-CR8020 (IgG)) and, 
in turn, evaluated whether the viral or cellular membrane could sterically hinder with the 
complex (Figure 2A–D and METHODS). Both FcγRIIa and FcγRIIIa were chosen for this 
modeling analysis because these are the two common activating FcγRs in humans. Our 
structural modeling shows that the membrane could sterically hinder the formation of HA-
CR8020-FcγRIIa and HA-CR8020-FcγRIIIa ternary complexes (Figure 2A–D). Because 
only one of the activating FcγRs (FcγRIIIa) can potentially engage with CR8020 (Figure 
2B), this could possibly decrease the biological activity and potentially the clinical efficacy 
of the antibody, given that it is unclear which FcγR could dominate in vivo. A similar 
modeling exercise performed on a different stem-binding antibody, FI6, which binds higher 
up the stem region than CR8020, demonstrated that the antibody may have a higher potential 
to form the ternary complex with HA and both activating receptors, FcγRIIa/FcγRIIIa (data 
not shown). This is supported by the recent study, which showed that PR8 virus-FI6 immune 
complex efficiently binds to FcγRIIIa receptor (Dilillo et al., 2014). Furthermore, 
comparison of CR8020 to an antibody binding the trimeric interface indicates that CR8020 
is ~10-fold less potent in eliciting ADCC, measured as either concentration of onset or fold-
induction (Figure 2E). Altogether, the experimental data combined with the results of our 
modeling analyses indicate that location and mutability of the epitope could play critical 
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roles in determining the efficacy (or lack of) of CR8020 in the clinical setting. In most 
preclinical virus-challenge experiments, dosing of the antibody and the different strains of 
mice or ferrets is likely measuring the ability of the bNAbs to directly neutralize virus in 
vivo. However, the recent study published with humanized mice expressing human FcγR 
suggests that Fc-FcγR interactions do play a key role for at least two of the anti-stem bNAbs 
tested and that at higher doses the in vivo protection can be independent of the Fc-FcγR 
interaction (Dilillo et al., 2014). The Fc-FcγR interaction requirement is well established for 
antibodies that are used for other indications such as cancer. The results of our analyses have 
practical implications for designing human influenza clinical trials using bNAbs. 
Importantly, dosing regimen, Fc engineering (for maximum affinity towards activating 
FcγRs), and careful recruitment of patient population (keeping in mind FcγR polymorphism) 
need to be considered for clinical trial design.
DISCUSSION
In our modeling of the activation complex, the oligomeric state of FcγRIIa/FcγRIIa is kept 
as a monomer. Although it is believed that FcγRIIa is constitutively present as a dimer on 
the cell surface, the exact oligomeric state of FcγRIIa in the HA–IgG–FcγRIIa complex has 
not been characterized. Nevertheless, modeling the activation complex with the 
crystallographic dimer of FcγRIIa (source PDB: 1FCG) does not alter the results of our 
analysis (data not shown).
Dilillo DJ et. al., suggest that conformational changes induced in the Fc upon binding to the 
epitope could be the reason for the difference in the ADCC potential of anti-stem mAbs in 
comparison to anti-head mAbs. Although our analysis does not take into consideration Fc 
conformational changes, the Fc:FcγR modeling analysis suggests that steric hindrance could 
also be a major factor in the differential FcγR engaging capacities. Although Dilillo DJ et. 
al., demonstrated differences between anti-head mAbs versus anti-stem mAbs in their ability 
to engage FcRs, our analysis goes one step above to explain the striking differences in 
ADCC mediated cell killing between two anti-stem bNAbs.
In light of the limitations of CR8020 identified by this study and the importance of antiviral 
strategies against group 2 viruses such as H3N2 and H7N9, bNAbs that target epitopes that 
are accessible to immune complex assembly and less susceptible to mutations are desired. 
Generally, epitopes that are closer to the viral membrane harbor the most conserved and 
highly networked epitopes with broad spectrum neutralizing potential; however location of 
the epitope could impose constraints on accessibility. Conversely, epitopes on the globular 
head are accessible but are susceptible to rapid antigenic drift (Figure S2). Therefore, both 
epitope mutability and accessibility to immune complex assembly are important attributes to 
factor in as one evaluates suitable antibody candidates for clinical development.
Finally, we believe that these results have important ramifications for vaccine design. 
Multiple of the broadly neutralizing antibodies originate from the Vh1-69 germline (Friesen 
et al., 2014; Hwang et al., 2014). On the basis of the CR8020 data, strategies focused on 
activation of this germline may not be ideal to elicit full spectrum protection. Instead, 
activation of other germlines, such as Vh3–30, may provide a better solution.
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EXPERIMENTAL PROCEDURES
Capturing network of protein residues (SIN)
The coordinates of A/X-31(H3N2) HA trimeric complex (PDB: 1HGG) and A/Shanghai/
02/2013(H7N9) HA (PDB: 4LN3) were used to compute highly networked residues. For 
each case, various inter-residue inter-atomic contacts including putative hydrogen bonds 
(including water-bridged ones), disulfide bonds, pi-bonds, polar interactions, salt bridges, 
and Van der Waals interactions (non-hydrogen) occurring between pairs of residues were 
computed as described previously (Soundararajan et al., 2011). The data was assembled into 
an array of eight atomic interaction matrices. A weighted sum of the eight atomic interaction 
matrices was computed to produce a single matrix that accounts for the strength of atomic 
interaction between residue pairs, using weights derived from relative atomic interaction 
energies (Soundararajan et al., 2011). The inter-residue interaction network calculated in this 
fashion generates a matrix that describes all the contacts made between pairs of residues. 
Each element i, j is the sum of the path scores of all paths between residues i and j. The 
degree of networking score for each residue was computed by summing across the rows of 
the matrix, which corresponds to the extent of “networking” for each residue. The degree of 
networking score was normalized (SIN score) with the maximum score for the protein so 
that the scores varied from 0 (absence of any network) to 1 (most networked). From the 
previous study, residues with a SIN score ranging from 0 to 0.2 are considered poorly 
networked, those with 0.2–0.5 are considered moderately networked, and those with >0.5 
are highly networked.
Sequences, amino acid variation and computation of coevolving residues
17,921 sequences of the H3N2 HA of human, avian and swine H3N2 strains isolated 
between 1934 and 2014 were downloaded from fludb.org. From this, laboratory sequences, 
especially mutants, were excluded. If multiple sequences were present for the same strain, 
only the consensus was included. Additionally, only sequences that have complete coding 
regions including start and stop codons were considered. The above procedure yielded 3,794 
full-length, non-redundant sequences. A similar procedure when applied to human, avian 
and swine H7N9 HA yielded 612 full-length, non-redundant sequences. The sequences were 
aligned using MUSCLE (Edgar, 2004). Then, we computed the extent of variation at each 
position with the SNP tool at fludb.org. From the alignment, intramolecular co-evolving 
residues were computed with the CAPS server using default parameters (http://
bioinf.gen.tcd.ie/caps/home.html).
Computational prediction of H3 & H7 escape mutations with CR8020-HA co-crystal 
structures
Mutations detrimental to the epitope-paratope interface were first computed with a built-in 
binding energy scoring function in Discovery Studio, which performs amino-acid scanning 
mutagenesis on a set of selected epitope residues and evaluates the effect of single-point 
mutations on the binding affinity of molecular partners. Then, to assess whether a mutation 
can impact the stability of HA, the inter-residue interactions were computed upon modeling 
that residue on HA. A mutation is considered to be harmless if it maintains the inter-residue 
interaction network (determined by SIN) similar to that of the wild type.
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Modeling the HA-IgG-FcγRIIa/HA-IgG-FcγRIIIa ternary activation complex
The modeling was carried out in two steps. In step one, the Fab arm of a human IgG1 (from 
X-ray crystal structure PDB: 1HZH) was superposed onto the CR8020-HA co-crystal 
structure (PDB: 3SDY). Because Fab and Fab’ are positioned differently relative to the Fc, 
two different models of IgG-HA interactions were obtained. In step two, the FcγRIIa 
receptor from PDB: 3RY6 and FcγRIIIa receptor from PDB: 3AY4 were docked against the 
Fc by superposing the Fc:FcγRIIa/Fc:FcγRIIIa co-crystal structure on the Fc region of the 
IgG-HA complex. A similar procedure was carried out to obtain the HA-FI6-FcγRIIa/
Fc:FcγRIIIa ternary activation complex. Structural alignment and visualization were 
performed with PyMOL.
ELISA binding assays
Recombinant hemagglutinin (Protein Sciences Corporation) was coated on 96-well 
microtiter plates (Immuno™ Maxisorp, Nunc) and blocked with 5% Blotto (Santa Cruz 
Biotechnology) in 1x PBS. Serially-diluted CR8020 antibody, whose sequence is described 
in patent PCT/EP2010/056217 (Throsby, 2010), was added, and binding detected using 
horseradish-peroxidase-conjugated goat anti-human IgG (Fc specific) (Bethyl Labs) 
followed by development with 3,3,5,5- tetramethylbenzidine solution (KPL). The 
absorbance at 450 nm was measured using a Spectramax plate reader (Molecular Devices) 
and data analyzed with the Softmax software.
Measurement of Antibody-Dependent Cellular Cytotoxicity
CR8020 and an antibody targeting the trimeric interface were tested for their ability to 
mediate FcγRIIIa engagement. Target cells were created by infecting A549 cells with A/
Victoria/3/75 (H3N2) at a multiplicity of infection ~1.0 for 18 hours, after which cells are 
seeded into a white 96-well plate. Control experiments employing fluorescence-activated 
cell sorting indicated that both antibodies bound to infected cells. The ADCC Reporter 
Assay from Promega was used to assess killing with an assay control of an anti-CD20 mAb 
added to WIL2-S cells. Dilutions of “Test” & “Control” mAbs were added to Target cells, 
and engineered effector cells (Jurkat T-cells transfected with CD16 (V/V 158 variant) and 
NFAT-Firefly Luciferase Gene) are added to wells and allowed to incubate for 6 hours at 
37°C. Then, Bio-GLO Luciferase substrate solution was added to wells in order to measure 
activation of FcγRIIIa and results read on a luminometer.
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HIGHLIGHTS
• HA residues targeted by the CR8020 antibody are susceptible to host selection 
pressure
• Influenza HA mutations have the potential to negatively impact CR8020 activity
• Known CR8020 escape mutation is found in at least one H7N9 outbreak virus
• Membrane may sterically hinder FcγR binding to Fc within the HA-CR8020 
immune complex
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Figure 1. Coevolution of stem residues and measurement of CR8020 binding to various H3 and 
H7 strains
(A–D) Coevolution between residues at 19 (HA2) and 326 (HA1) in H3 and H7 are shown 
in A & B, respectively, and coevolution between residues at 19 (HA2) and 160 (HA2) in H3 
and H7 are shown in C & D, respectively. In the alignment of 3,794 H3 sequences, the 
amino acid at position 19 of HA2 is conserved at 98.91% as aspartic acid (83.93% 
conservation in 612 H7 sequences). When aspartic acid at 19 mutates to asparagine, 
mutations occur in structurally proximal positions, referred as co-evolution. A similar trend 
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is observed in H7 subtype also. The frequency of mutation (instances of deviance from the 
conserved residue) as observed year-by-year in reported H3 and H7 sequences is 
demonstrated. A frequency of 0.0 means the position was entirely conserved in all sequences 
from that year, and frequency of 1.0 means that all sequences from that year possessed a 
mutation at the given position. Mutation frequency charts show the temporal covariance of 
the co-evolving residues. (E) Location of the coevolving residues on the stem region of HA. 
The main chain of HA (PDB: 1HGG), colored in gray, is shown in cartoon format, and the 
solvent accessible surface shown in transparency. The side chain atoms of the co-evolving 
residues are represented by spheres (red). All the images in the manuscript were rendered in 
PyMOL. (F) The ability for CR8020 to bind to influenza HA was measured, (○) H3N2 (A/
Wyoming/3/2003); (●) H3N2 (A/Brisbane/10/2007); and (▼) H7N9 (A/Shanghai/02/2013). 
Also included was a BSA control (Δ), coated instead of hemagglutinin to ensure no non-
specific binding. Figure 1F are the result of a representative experiment. The full binding 
curve was completed three times and an apparent Kd expressed as an average + standard 
deviation was determined. CR8020 bound A/Wyoming/3/2003 (H3N2) very strongly with 
an apparent Kd of approximately 60 pm (individual measurements of 57, 59, and <80 pM). 
CR8020 bound A/Brisbane/10/2007 (H3N2) with an apparent Kd of 3.36 + 1.97 nM. 
Binding to H7N9 A/Shanghai/02/2013 (H7N9) and A/Anhui/1/2013 (H7N9) was too weak 
in this assay to determine an apparent Kd. See also Figure S1.
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Figure 2. Modeling the HA-CR8020-FcγRIIa/HA-CR8020-FcγRIIIa activation complex and 
measurement of cell killing by anti-influenza antibodies
(A–D) The CR8020-HA complex crystal structure (PDB: 3SDY) was used to model the 
IgG-HA interaction. Given the different orientations of the two Fab domains (from here 
onward referred to as Fab and Fab’) with respect to the Fc, as observed in the human IgG1 
X-ray crystal structure (PDB: 1HZH), two different IgG-HA models were constructed 
(METHODS) where, in one case, Fab was docked against the H3, and, in the other, Fab’ 
was docked against the H3 (A & C). Then, FcγRIIa and FcγRIIIa, represented by solvent 
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accessible surface and colored in gray and magenta, respectively, were docked against Fc in 
a fashion (METHODS) that mimics their interaction seen in the Fc:FcγRIIa (PDB: 3RY6) 
and Fc:FcγRIIa (PDB: 3AY4) co-crystal structures (B & D). In the first model, the FcγRIIIa 
is proximal to the membrane, which could cause steric hindrance; interaction with FcγRIIa 
is sterically hindered by the membrane (B), whereas, in the second model, the Fab domain is 
oriented too close to the viral membrane, which suggests that the model is not plausible (C 
& D). (E) The ability for CR8020 (■) and an antibody targeting the trimeric interface (▲)to 
lyse influenza-infected A549 cells was measured. A IgG binding to an irrelevant antigen (◆) 
showed no activity in this assay. Results are shown as an average + standard error (n=3). See 
also Figures S2.
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